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IL-1j, a major stimulator of hyaluronan synthesis in vitro of human
peritoneal mesothelial cells: Relevance to peritonitis in CAPD. The effect
of several different growth factors and cytokines on the synthesis of
hyaluronan (HA) by human peritoneal mesothelial cells (HPMC) was
investigated. Growth arrested HPMC synthesized low levels of HA, but
co-culture with PDGF-bh, TGF-f31, TNF-a, and IL-6 at a concentration of
10 nglml all increased HA synthesis between two- to three-fold. At the
same concentration IL-113 significantly increased the synthesis eight-fold
(N = 3; P < 0.05). The effect of IL-1J3 was also dose- and time-dependent
and could be totally negated with interleukin-1 receptor antagonist (IL-113
RcA). Non-infected and infected dialysate from patients receiving CAPD
was also found to stimulate HA synthesis by HPMC. The levels found with
non-infected fluid were 4 >< io dpm/ml (N = 6) and 12.9 X iO dpm/ml(N = 6; P < 0.002) and 8.7 >< iO dpm/ml (N = 6; P < 0.003) for infected
fluid collected one and two days after the commencement of peritonitis.
IL-1 RcA dramatically reduced the effect of infected but not non-
infected dialysate. These results provide new insights into the manner in
which HA synthesis is controlled in the mesothelium and suggest that
IL-113 is a key cytokine in the inflammatory response in CAPD patients.
Hyaluronan (HA), also known as hyaluronic acid, is an impor-
tant glycosaminoglycan (GAG) found in the extracellular matrix
and at cell surfaces as part of the pericellular matrix [1—3]. HA is
an alternating copolymer of N-acetyl-D-glucosamine and D-
glucuronate, that unlike the GAGs found in proteoglycans, is
neither sulphated nor covalently attached to a core protein.
However, a number of proteins including link protein [4], hyalu-
ronectin [5], and the core proteins of aggrecan [6] and versican [7,
8] have specific affinity for HA. In addition two cell-surface
receptors for HA have been cloned [9, 101.
HA plays a critical role in joint function and is responsible for
the rheological and viscoelastic properties of synovial fluid. In
addition to these physical properties, HA has been implicated in
cell locomotion during embryogenesis, tumor invasion and in
response to injury [11. HA is also thought to play a critical role in
tissue remodeling after injury and in the inflammatory process.
Recently we reported on the metabolism of HA in patients
receiving continuous ambulatory peritoneal dialysis (CAPD) for
the treatment of end-stage renal failure [Ii]. These studies
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showed that the process of CAPD results in an increase in HA
levels in the peritoneal cavity and that during episodes of perito-
nitis these levels are significantly augmented. While the cellular
origins of HA in normal or infected peritoneum were not inves-
tigated the serum levels of HA in the CAPD patients were
considered too low to account for the increased concentrations in
the fluid during bacterial infection. The probable source of the
increased HA in the dialysate is therefore likely to be the
peritoneal mesothelia! cell. These cells in vitro synthesize HA,
very little of which is retained by the cell but is secreted into the
culture medium. Furthermore, in an experimental model of
inflamed peritoneum in the guinea pig, it was shown that cells of
the mesentrium synthesize HA, and that inflammatory changes in
the peritoneal lining are critical to the initiation of increased HA
production [12].
The molecular mechanism of regulation of the production of
HA in the peritoneum is unknown, but many agents have effects
on HA synthesis in pleural mesothelial cells and fibroblasts
[13—16]. Principal among these agents are growth factors, includ-
ing platelet derived growth factor (PDGF), basic fibroblast growth
factor (bFGF), transforming growth factor (TGF) /3 and epider-
ma! growth factor (EGF). In addition, the regulation of lung
fibroblast glycosaminoglycan (GAG) production including HA
appears to be influenced by interferons, tumor necrosis factor
(TNF-cx) and lymphotoxin [13]. These observations have led us to
speculate that growth factors and eytokines may be important
regulators of the levels and quantity of HA in the peritoneum.
Consequently, we have investigated the effect of several peptides
and dialysate from patients receiving CAPD on the synthesis by
human peritonea! mesothelial cells (HPMC) of HA in vitro. The
results suggest that interleukin-1f3 (IL-1[3) has a pronounced
effect on HA by HPMC and emphasize the potential role of this
cytokine in the control of HA in the peritoneum.
Methods
Clinical material
The samples of spent dialysis fluid used in this study were all
from patients receiving treatment for end-stage kidney failure by
CAPD in the Renal Unit, Royal Infirmary, Cardiff, Wales. Six
samples were from patients when free of infection (referred to as
non-infected fluid) and six during an episode of peritonitis
(referred to as infected fluid). They were aged 18 to 84 years.
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Samples were taken from overnight dwell (8 to 10 hr) bags. The
samples were centrifuged at 1000 g for 10 minutes to remove
debris, and then the clear supernatant was aliquoted and stored at
—20°C until used in the co-culture experiments. For some exper-
iments two pooled samples were prepared. This was achieved by
pooling 0.5 ml of each sample from non-infected (N = 6) and
infected fluids (N 6), respectively.
Culture and radiolabeling of mesothelial cells.
Human peritoneal mesothelial cells (FIPMC) were isolated
from human omentum and cultured essentially as reported by us
previously [171, except that the medium was Medium 199 (Gibco,
Paisley, Scotland, UK), which contained 10% fetal calf serum
(FCS, Gibco) and was supplemented with hydrocortisone (Sigma
Ltd, Poole, UK). For radiolabeling, cells were seeded at a density
of 2 X 105/cm2 in 24-well culture plates (Falcon), incubated until
confluent, growth arrested in serum-free medium for 48 hours,
and then labeled for 24 hours with fresh serum-free medium
containing D-[6-3H]-glucosamine hydrochloride (25 LCi/ml;
sp.act. 20 Ci/mmol, Amersham International UK). The medium
was then removed and retained and the cell layer washed with
Medium 199 without serum or radioisotope, the washings being
added to the medium. The cell medium and the cell layer both
were digested with papain (20 g/ml in 0.2 M sodium acetate, pH
5.8 buffer) for 16 hours at 60°C and the products analyzed on a
Mono-Q anion exchange column (Pharmacia), equilibrated with
urea buffer comprising 8 M urea, 0.15 M NaCl, 20 mrvi Bis-Tris, pH
6.0, containing 0.1% (wt/vol) CHAPS and interfaced with an fplc
system (Pharmacia). The column was developed with a linear
gradient of NaCI in urea buffer and fractions (0.5 ml) were
collected and analyzed for radioactivity. The material, which
eluted between 0.3 to 0.4 M NaCl contained the newly synthesized
[3H]-HA [8]. To confirm the presence of HA metabolism and to
estimate its molecular size, samples were passed over an analytical
Sephacryl-500 (Pharmacia) (0.6 X 150 cm, equilibrated in 4 M
guanidine, 50 mM sodium acetate, pH 6.0, containing 0.5% Triton
X-100) before and after treatment with Streptomyces hyaluroni-
dase (50 mU/mI; Sigma, Poole, UK) for 16 hours [11].
Co-culture of human mesothelial cells with peritoneal fluid,
cytokines and growth factors
Human peritoneal mesothelial cells were established in 24-well
plates and growth arrested as described above. The culture
medium was then removed and the cells washed twice with PBS.
The culture was then continued in serum-free medium containing
different concentrations of cytokines or dialysate, suitably diluted,
and D-[6-3HJ-glucosamine hydrochloride (25 iCi/ml). The level
of HA synthesis was established by the incorporation of 3H-
glucosamine into papain-resistant, hyaluronidase-degradable ra-
diolabeled high molecular weight glycosaminoglycans (GAGs) as
above. In the experiments with the added cytokincs the level of
HA was also measured using a specific ELISA. This assay was
unsuitable to determine the effect of dialysate on HA synthesis
because the fluid itself contains high levels of endogenous HA.
Cell numbers were determined by direct counting using a modi-
fied Neuhauer hemocytometer. The cytokines were obtained from
R&D Systems Europe, Ltd., Oxon, UK. lnterleukin-i receptor
anatgonist was a gift of Dr. Luke O'Neill, Trinity College, Dublin,
Ireland.
Determination of HA levels by ELISA
Prior to assay the culture medium was digested with papain and
the HA was determined using an ELISA protocol as described by
Forsang et al [18]. The assay involves the competition between
HA adsorbed to microtiter plates and HA in solution for binding
to the binding region of the Gi domain of aggrecan. This material
was donated by Dr. M.T. Bayliss, Kennedy Institute, Hammer-
smith, England, UK. To assess the effect of serum on HA
synthesis as determined by the ELISA, the FCS was passed over
a DEAE-Sephacel column to remove any endogenous HA prior
to culture with HPMC.
Determination of IL-i levels in dialysate
IL-1 was determined by enzyme immunoassay, using kits
obtained from Modyinex Diagnostis (Fleurs, Belgium) as de-
scribed by Brauner, Hylander, and Wretlind [19].
Statistics
Results are expressed as means SD and range as appropriate
and compared using the Student's t-test.
Results
The determination of levels of hyaluronan (HA)
The biosynthesis of HA by HPMC was determined by metabolic
labeling of the cells with [3H]-glucosamine for 24 hours, followed
by analysis of the labeled macromolecules extracted from the cell
layer and culture medium after digestion with papain. The
digested products were concentrated on a Mono-Q anion ex-
change column, and the bound material was eluted between 0.3 to
0.4 M NaCl (Fig. 1A) analyzed using an analytical Sephacryl-500
column under dissociative conditions. The material eluting in the
void volume (Fig. 1B) represents [3H]HA. Positive identification
of HA was made by treatment of the [3H]HA with Streptomyces
hyaluronidase, which degrades HA but not heparan sulphate or
chondroitin sulphate/dermatan sulphate glycosaminoglycan
chains to disaccharides. Growth arrested cells synthesized very
little HA but the inclusion of FCS significantly stimulated the
production of the polysaccharide. The distribution of 3H-labeled
HA indicated that the majority of the HA synthesized by the
HPMC was secreted into the culture medium (>95% of the total)
and consisted mainly of a high molecular form eluting in the void
volume together with a smaller species which appeared as a
shoulder (Kay 0.2; Fig. IB). Very little HA was observed below a
K, of 0.4, nor was there any evidence of degradation products.
The material from each fraction was also concentrated and
assayed for HA using an ELISA employing the biotinylated Gi
domain (HA-binding region) of aggrecan [18]. The elution profile
determined with this assay confirmed the distribution and size of
the metabolically labeled HA (data not shown).
IL-1f3 but not IL-6, TNF-a, TGF-p or PDGF-hb has a profound
effect on the synthesis of HA by HPMC
Co-culture of HPMC with different cytokines for 24 hours
increased the levels of extractable [3H]-HA from the cell layer and
culture medium when compared to control cultures (Table 1).
These experiments were undertaken with quiescent cells and over
the time period of the co-culture there was no increase in cell
numbers. Four of the cytokines tested, IL-6, TNF-a, TGF-J3 and
PDGF-bb, had a relatively modest effect on [3H]HA synthesis. At
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Fig. 1. Radiolabeling assay for hyaluronan (HA). HPMC were metaboli-
cally labelled with [3H]-glucosamine for 24 hours, the culture medium and
cell layer digested with papain and processed as described in Methods on
a Mono-Q anion exchange column. (A) The material eluting between 0.3
and 0.4 M NaCl represents f3H]-HA. Pooled fractions obtained from cells
grown in serum-free medium (0) and FCS (•) were passed separately
over a S-500 column. (B) The 13H]-HA derived from FCS cells was also
analyzed after treatment with hyaluronidase (•).
a dose of 10 ng/ml, there was approximately a 1.7 to 2.9-fold
significant increase for each of these peptides. In contrast, IL-113
at the same dose dramatically increased the levels of [3H]HA. At
a concentration of 10 nglml there was an eight-fold increase in HA
synthesis compared to control cells. To confirm the above results,
the HA levels after treatment with the different cytokines were
also determined using the HA-binding assay. The levels of HA
detected in the cells and medium treated with the different
peptides confirmed the findings with the radiolabeling assay (Fig.
2). The effect of IL-1p was both dose- and time-dependent (0 to
24 hr) (Fig. 3). Table 1 also indicates that FCS (10%) induced a
24.3-fold increase in 1-IA synthesis.
Table 1. Effect of FCS, TGF-J3, PDGF-bb, IL-6, TNF-a, and IL-1J3 on
hyaluronan synthesis by HPMC in vitro
Growth factora [3H]-HA synthesis5 Increasec
Control 6028 317 1
FCS (10%)
TGF-/3
PDGF-bb
146750 1460d
11935426d
10247 520d
24.3
1.98
1.7
IL-6 17481 576' 2.9
TNF-cs 10549 276d 1.75
IL-I /3 48585 906" 8.06
0
CONT 10% TGFI3 PDGF TNF IL-6 lL-1
FCS
Fig. 2. Level of HA in the culture medium of HPMC stimulated with
different growth factors and cytokines. The experiments were carried out as
described in Table 1 and the HA determined using the HA-binding
ELISA protocol as described in Methods. The results are mean of two
experiments with two different cell lines.
Analysis of the data indicated that after treatment with IL-i j3
there was no change in the distribution of [3HJHA, and >95% was
recovered in the culture medium.
Having determined that IL-I 13 greatly enhanced the synthesis of
HA by HPMC, we next investigated the effect of interleukin-113
receptor antagonist (IL-1f3 RcA) on the up-regulation. Cells were
treated with IL-1J3 (1 and 5 ng/ml) with and without IL-1p RcA
(100 ng/ml). IL-1p RcA itself had no effect on the growth of the
cells, nor was it toxic. Furthermore, the antagonist when added to
the culture medium alone had no direct effect on the synthesis of
HA. IL-1j3 RcA, however, did block the IL-1J3 dependent increase
in {3H]-HA (Fig. 4). At a 100-fold excess the IL-1/3 RcA com-
pletely prevented the enhanced synthesis, whereas at a 20-fold
excess the synthesis was reduced over control by 40%.
Co-culture of HPMC with peritoneal dialysate
To extend our studies on the metabolism of HA by HPMC, we
co-cultured these cells with dialysate obtained from patients
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Fig. 3. Time- and dose-dependent response of IL-1/3 on HA synthesis by
HPMC. Cells were co-cultured with, (A) IL-1J3 (0—b ng/ml) for 24 hours,
and (B) with (U) and without () TL-1j3 (10 nglml) for the times indicated.
HA synthesis was measured as described in Fig. 1. The results are
expressed as means SD (N = 3) from three different cell lines.
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Fig. 4. The effect of interleukin-J receptor antagonist (IL-1f3 RcA) on the
synthesis of HA by HP/tIC. Cells were growth arrested and then cultured
with IL-113 (1 or 5 nglml) with and without IL-1RcA (100 ng!ml). HA
synthesis was measured as described in Fig. 1. The results are the average
of two separate experiments.
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Fig. 5. HA synthesis by HPMC co-cultured with dialysate fluid from patients
receiving CA PD. Growth arrested HPMC were incubated for 24 hours with
dialysate obtained from patients with no infection (0) (N = 6); fluid from
day I of infection (S) (n = 6) and fluid from day 2 of infection (A) (N =
6). HA synthesis is expressed as [3H1-HA dpm/ml. The bar indicates the
mean value for each group. The results for infected fluid at Day 1 (* P <
0.002) and Day 2 (** P < 0.003) were significantly higher than those for
control dialysate.
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receiving CAPD for the treatment of end-stage renal failure. For
this study, pooled dialysate was prepared from patients free of
infection and from patients on day I and day 2 of an episode of
peritonitis. As shown in Figure 5, the separate addition of these
three different sources of fluids induced an increase in HA
synthesis. The response to the infected fluids, however, both from
day 1 and day 2, was significantly greater than that of the
non-infected. The stimulation of HA synthesis by both infected or
non-infected dialysate was dependent on the concentration of the
fluid and incubation time (data not shown). We were unable to
demonstrate that unused dialysate at dilutions greater than one in
five had any effect on HA synthesis by HPMC. Taken together,
the above results suggest that the composition of the dialysate
itself is not responsible for the observed enhanced synthesis of HA
but rather an agent(s) acquired by the fluid during the period of
dialysis is involved. Furthermore, dialysates from patients with
peritonitis contain significantly higher amounts of this agent or
agents.
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Fig. 6. Effect of IL-1/3 RcA on the synthesis of
HPMC co-cultured with dialysate. Cells were co-
cultured with dilutions of dialysate from
patients free of infection (A) and day I of
infection (B) with •) and without (0) IL-113
RcA (100 nglml). Results are the average of
two experiments with two cell lines.
Since in the experiments described above we demonstrated that
IL-1/3 had a potent effect on HA synthesis by HPMC, experiments
were directed at determining whether IL-1/3 RcA caused a
reduction in the level of HA extracted from the cell layer and
culture medium. For these experiments, dilutions of dialysate
(1/20 to 1/2) were employed and incubated with and without 100
nglml of IL-Ip RcA. Figure 6. clearly shows that the response of
the cells to infected fluid was reduced with an increasing ratio of
the IL-1f3 RcA to dialysate. When the incubation was undertaken
with 1 in 20 dilution of dialysate, the effect of the antagonist was
to reduce the synthesis of HA by 95%.
In contrast, using the same dilutions and concentration of
IL-1RcA, there was little or no reduction in the synthesis of HA
with the non-infected fluid. This result suggests that IL-lp is not
the agent responsible for the small increase in HA synthesis
induced by non-infected fluid, as recorded in Figure 5.
To further extend the above observations, we measured the
levels of IL-1f3 in both sources of dialysate. The average levels in
dialysate from patients with infection were between 18 to 40 pg/ml
(average, 24 pg/mI; N = 8) for the first day of the infection. For
day 2 of infection the levels in the dialysate of two patients
investigated were lower (12 and 13.5 pg/ml, respectively). In
contrast, the levels in fluid from six patients without peritonitis
were undetectable. These findings are in agreement with the
recent report by Brauner, Hylander, and Wretlind [19].
Analysis of the 311-labeled HA extracted from control and
stimulated cells
[3H]-HA derived from control cells and cells stimulated with
lL-113 (10 ng/ml), non-infected and infected dialysate, and FCS
were analyzed on an analytical Sephacryl-500 column. Compari-
son of the individual profiles confirmed that the size distribution
of the [3H]-HA did not vary from control cells or cells grown in
the presence of FCS (data not shown). The profiles failed to show
the appearance of any lower molecular weight HA, nor was there
any evidence of degradation products of HA.
Discussion
In this study we demonstrate that HPMC co-cultured with
IL-1/3 induces a significant increase in HA levels, whereas PDGF-
bh, TGF-13, TNF-cs and IL-6 were all less effective. The relative
increase in HA synthesis was demonstrated by using two different
approaches, both of which gave comparable results for each
cytokine and growth factor studied. At a dose of 10 ng/ml, IL-lp
was capable of up-regulating HA synthesis by as much as eight-
fold, whereas with all the other factors investigated the increase
was about two-fold. Analysis of the molecular weight of the HA
synthesized by the cells co-cultured with IL-113 indicated that it
was identical in size to HA from control cells. Furthermore, with
both control and cytokine stimulated cells the majority of the HA
(>95%) was located in the culture medium. These findings
minimize potential ancillary effects, such as changes in metabo-
lism, which contribute to the accumulation of HA. Finally, the
results with IL-1/3 and the other cytokine and growth factors were
not explained by changes in cell number.
HA is synthesized by a membrane bound enzyme, hyaluronan
synthetase [20—22], through the addition of monosaccharides to
the reducing end while the polysaccharide is extruded through the
plasma membrane and shed into the extracellular space. The
activity of the HA synthetase is regulated by a number of different
cytokines and growth factors alone or in combination, and for
most of these factors has been shown to be directly related to the
synthesis of the protein [13, 15]. To date, the factors investigated
include TGF-13, TNF, and bFGF, as well as lymphotoxin and
is-interferon [13, 15, 16, 23, 24]. The cell systems studied include
synovial lining cells, ovarian cells from different sources, and
human pleural mesothelial cells. With all these cells the effect of
co-culture with the above factors was to increase HA synthesis by
up to two-fold. The results from the present investigation for
PDGF-bb, TGF-p and TNF-a are in keeping with this level of
increase and furthermore indicate that IL-6 induces a similar
response. The synthesis of HA in response to IL-lp is less
well-documented, but in human chorionic cells [25], rat ovarian
cells [26] and synovial fibroblastic cells [27], this cytokine appears
to play a pivotal role in the accelerated biosynthesis and secretion
of HA. A preliminary report has indicated that IL-1 (1 ng/ml)
caused a small increase in HA synthesis in human mesothelial
cells [28]. These experiments, however, were undertaken with
cells grown in 10% FCS, and therefore already conditioned to
synthesize HA. Our experiments were undertaken with quiescent
cells and clearly show that IL-lp stimulates HPMC to synthesize
HA in a dose- and time-dependent manner. Furthermore, this
increase could be completely negated by IL-lp RcA.
The mechanism of regulation of HA by IL-1/3 in mesothelial
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cells remains to be investigated, and at present it is not known
whether there is increased HA synthetase activity at the cell
membrane or if other mechanisms such as changes in the intra-
cellular pools of the precursors UDP-N-acetyl-D-glucosamine and
UDP-D-glucuronic acid could be responsible. PDGF driven reg-
ulation of HA requires de novo synthesis of protein in which
protein kinase c participates positively in the transduction signal
[16, 29]. The IL-1p accelerated HA synthesis in chorionic cells is
also accompanied by increased hyaluronate synthetase activity,
which again in part appears to be regulated by protein kinase c
[25].
In the present study, we have also investigated the effect of
dialysate from patients receiving CAPD on HA synthesis by
resting HPMC. The results from these experiments show that,
whereas non-infected fluid promoted very little HA accumulation,
infected fluid initiated a dramatic increase in extracellular HA.
This preferential promotion of HA by the dialysate of patients
with active peritonitis could be inhibited by the inclusion of IL-1J3
RcA in the incubation medium. Furthermore, IL-113 was detected
in dialysate from patients with peritonitis while it was absent in
healthy patients. These results, taken together with the finding
discussed above, that among a number of different factors inves-
tigated IL-1/3 was the most effective in the up-regulation of HA by
HPMC, suggest that the same eytokine is the principal agent
present in infected fluid to explain our previous findings that HA
levels are elevated in patients with peritonitis [ii]. It was also
shown that the receptor antagonist had little effect on the small
increase in HA synthesis initiated by non-infected fluid, implying
that IL-1f3 is not present in non-infected dialysate. It is also
possible that in non-infected fluid the levels of cytokine are too
low to invoke a significant response, or that any functional effect
of peritoneal IL-1/3 is blocked by IL-i/3 RcA. It has been
demonstrated that in vitro, to achieve a 50% reduction in a
physiological response to IL-113, a 100-fold excess of antagonist is
required [301. The levels of IL-1f3 and its specific antagonist have
not been extensively studied in CAPD patients; however, two
recent reports have indicated that both of these molecules are
significantly elevated in the serum and dialysate of patients with
infection compared to those without peritonitis [19, 31]. Our
findings with the levels of IL-113 are in agreement with both these
groups. A finding in both the above reports is relevant to the
present studies, in that IL-1f3 RcA, but not IL-113, was detected in
dialysate from peritonitis-free patients. This could well explain the
relatively low stimulation of HA synthesis by non-infected dialy-
sate. From the levels of antagonist and cytokine in the infected
dialysate from these studies it is difficult to predict if the fluids
would have an effect on HA synthesis (see above, and [30]). To
further understand the function of IL-1/3 in the inflammatory
response to bacterial infection or damage to the mesothelium with
long periods of dialysis, more information on the relative levels of
the cytokine and its antagonists, including their bio-availability
activity, is required. In addition, some information is required
either to support or eliminate a role for cytokines other than
IL-I 13 present in peritoneal fluid in the regulation of HA synthesis
in peritonitis.
The implied role for IL-i j3 in the regulation of HA levels within
the peritoneum raises the question as to the source of this
cytokine. Two possibilities exist: the HPMC themselves and
peritoneal macrophages. HPMC produce relatively low levels of
IL-113, but the levels are raised in cells treated with exogenous
IL-i/3, TNF-a or LPS [32, 33] It is worth recalling that stimulation
with a combination of LPS and IL-1f3 or LPS and TNF-c had a
significant synergistic effect on cytokine production [33]. It is also
interesting to note that this cytokine is able to act in a paracrine
manner to up-regulate the expression of genes for several differ-
ent cytokines and growth factors, including IL-1f3 itself [32].
HPMC are also a source of other cytokines, including TNF-a and
IL-fl [34], and their levels in the peritoneum are raised in
peritonitis [35—371. The peritoneal macrophage is the predomi-
nant cell in the peritoneum of patients undergoing CAPD and
forms the first line of defense in bacterial infection [38—40]. When
appropriately stimulated, these cells secrete a host of proinflam-
matory molecules, including IL-1f3. This and other cytokines
released by peritoneal macrophages also have the potential to
interact with the resident peritoneal mesothelial cells, and thus
form part of a peritoneal cytokine network [34]. At present it is
not known the extent to which activated peritoneal macrophages
can enhance HA synthesis by HPMC. Since they secrete IL-113,
and given the observations in the present report, it is likely that
macrophages could play a key role in controlling the contribution
of HPMC to the overall levels of HA in the peritoneum.
In conclusion, the results reported in this paper permit the
speculation that IL-ip is a major stimulator of HA in the
peritoneum during episodes of peritonitis. The implication of such
a response remains to be decided, but since HA is an important
component of the early events of wound healing [1], a role for
IL-113 in the control HA metabolism of the mesothelium is
possible. Recently, HA has been shown to be a constituent of the
vascular endothelial basement membrane, and that its selective
removal effects the passage of solute through the endothelium
liquid-exchange barrier [41]. The composition of the peritoneal
liquid-exchange barrier is not known in detail, but histochemical
studies have demonstrated the existence of anionic sites along the
peritoneal basement membrane and part of the protective glyco-
calyx that surrounds mesothelial cells [42]. In vitro studies have
clearly identified HA as a critical component of the glycocalyx of
cells [4345], which protects the cell from viral infection [43] and
the cytotoxic effect of lymphocytes [46, 47]. More importantly,
acute experimental peritonitis induces a reduction of the anionic
sites of the mesothelial cell glycocalyx, as well as the microvascular
mesothelial barrier [48]. The apparent rapid and early response of
HA synthesis by HPMC to IL-1/3 described in these studies could
suggest an attempt by these cells to limit the consequences of
peritonitis.
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